Top Page
Oxford BioDynamics
(LSE:OBD)
Oxford BioDynamics (OBD) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioDynamics Business Overview & Revenue Model
Oxford BioDynamics Financial Statement Overview
| Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 617.00K | 636.00K | 510.00K | 154.00K | 341.00K | 456.00K |
| Gross Profit | -7.49M | 289.00K | 266.00K | 116.00K | -557.00K | -166.00K |
| EBITDA | -9.32M | -10.27M | -9.84M | -6.16M | -6.43M | -4.42M |
| Net Income | -11.11M | -11.57M | -10.83M | -6.71M | -6.68M | -4.31M |
Balance Sheet | ||||||
| Total Assets | 11.07M | 12.11M | 16.13M | 11.34M | 15.38M | 15.35M |
| Cash, Cash Equivalents and Short-Term Investments | 1.19M | 2.83M | 5.25M | 999.00K | 4.34M | 11.51M |
| Total Debt | 6.00M | 5.74M | 6.44M | 6.14M | 6.59M | 541.00K |
| Total Liabilities | 9.44M | 7.75M | 10.07M | 8.76M | 8.69M | 1.77M |
| Stockholders Equity | 1.62M | 4.36M | 6.05M | 2.59M | 6.68M | 13.56M |
Cash Flow | ||||||
| Free Cash Flow | -7.46M | -10.77M | -9.01M | -6.08M | -9.01M | -3.86M |
| Operating Cash Flow | -6.71M | -10.17M | -8.29M | -5.18M | -5.92M | -3.40M |
| Investing Cash Flow | 1.68M | -1.49M | -691.00K | 1.25M | 2.83M | 4.58M |
| Financing Cash Flow | 5.03M | 8.25M | 13.42M | 2.56M | -804.00K | -181.00K |
Oxford BioDynamics Technical Analysis
Oxford BioDynamics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £11.35M | ― | -13.85% | ― | 7.27% | 39.64% | |
53 Neutral | £11.75M | ― | -333.59% | ― | 45.22% | 55.71% | |
53 Neutral | £20.95M | ― | -137.62% | ― | 10.50% | -9.60% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
46 Neutral | £9.71M | ― | -99.43% | ― | 17.39% | 96.02% | |
44 Neutral | £11.37M | ― | -129.49% | ― | 14.12% | 78.16% |
Oxford BioDynamics Corporate Events
Oxford BioDynamics PLC has announced a significant change in its shareholder structure following the acquisition of financial instruments by Trafalgar Capital Management (HK) Limited. This acquisition has resulted in Trafalgar Capital holding 3.3% of the voting rights in Oxford BioDynamics, marking a notable shift in the company’s ownership landscape. This development could potentially impact the company’s strategic decisions and influence its market position, as it reflects increased interest and investment from international stakeholders.
Oxford BioDynamics announced a joint webinar with Agilent Technologies to showcase their EpiSwitch 3D Genomic Platform, which utilizes Agilent’s SureScan microarray to explore 3D genome architecture for disease insights. This collaboration has been crucial in developing accurate and scalable clinical tests, such as the EpiSwitch PSE for prostate cancer detection and the EpiSwitch SCB for diagnosing canine cancers, enhancing the company’s position in precision medicine.
Oxford BioDynamics PLC announced a change in major holdings as Spreadex LTD adjusted its financial instruments, resulting in a slight decrease in its overall voting rights in the company. This adjustment reflects a minor shift in stakeholder positions, potentially impacting the company’s governance dynamics and signaling strategic financial maneuvers within the biotechnology sector.
Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring a significant portion of financial instruments, resulting in a total voting rights percentage of 3.0815%. This acquisition reflects Spreadex’s strategic interest in the company, potentially impacting Oxford BioDynamics’ market positioning and shareholder dynamics.
Oxford BioDynamics announced the successful use of its EpiSwitch blood-based biomarkers in a study conducted by Pfizer, which evaluated tumor status and treatment outcomes in cancer patients from the JAVELIN Bladder 100 Trial. The study demonstrated that EpiSwitch biomarkers can effectively determine immune activity levels in tumors, aiding in cancer treatment decisions and potentially revolutionizing cancer detection and monitoring. This advancement underscores the company’s potential for growth in the cancer diagnostics market and highlights the efficacy of its EpiSwitch technology, already proven in prostate cancer testing.
Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. This notification reflects a slight decrease in the total percentage of voting rights held by Spreadex, which may influence the company’s shareholder dynamics and strategic decisions moving forward.
Oxford BioDynamics Plc announced its interim results for the six-month period ending March 31, 2025, highlighting significant corporate and operational achievements. The company reported a substantial increase in revenue and cash reserves, driven by the growth in sales of its EpiSwitch PSE test and strategic agreements, such as the one with Bupa UK. Despite ongoing commercial discussions, no definitive deals have been secured, prompting the company to focus on preserving business integrity and optimizing shareholder value. The company also achieved ISO15189 accreditation for its UK lab and recorded its highest PSE sales in June 2025, indicating strong market acceptance and potential for future growth.
Oxford BioDynamics PLC has announced a change in its financial instrument holdings, as Spreadex LTD has adjusted its position in the company. The notification indicates that Spreadex now holds a total of 3.0049% of the voting rights in Oxford BioDynamics, reflecting a slight increase from its previous position. This adjustment may influence the company’s market dynamics and stakeholder interests as it continues to navigate the competitive landscape of the biotechnology sector.
Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.